|
|
|
 |
| Location: Home -
Products - Active Pharma Ingredients(API) - Prostaglandins
|
Beraprost sodium
| Catalogue No. : |
C13371 |
| Product Name: |
Beraprost sodium |
| Synonym: |
TRK 100;Procyclin;ML 1129 |
| Chemical Name: |
2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-1H-cyclopenta[b]benzofuran-5-butanoic acid, monosodium salt;Sodium 2,3,3a-8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-1H-cyclopenta[b]benzofuran-5-butanoate |
| CAS No. : |
88475-69-8 |
| Structure : |
|
| Molecular Formula: |
C24H29NaO5 |
| Molecular Weight: |
420.47 |
| Purity: |
>99% |
| Usage: |
Beraprost is an analog of prostacyclin in which the unstable enol-ether has been replaced by a benzofuran ether function. This modification increases the plasma half-life from 30 seconds to several hours, and permits the compound to be taken orally. Doses of 20-100 µg in humans, given 1 to 3 times per day, have been demonstrated to improve clinical end points in diseases responsive to prostacyclin. Oral beraprost therapy improved the survival and pulmonary hemodynamics of patients with primary pulmonary hypertension. Beraprost inhibits platelet aggregation in healthy subjects and in diabetic patients at similar doses. |
|
| Products protected by valid patents are not offered for sale in countries, where the sale of such products constitutes a patent infringement. As it is impossible for us to be informed about the patent situation in all countries, the liability for patent infringement is exclusively to be understood as buyer's risk. |
|
|
